UAE pharma giant Julphar completes restructuring exercise

Ras Al Khaimah company cancelled 503m shares equal to accumulated losses

Last updated:
1 MIN READ
Julphar starts on a fresh chapter from July 28, with the launch of trading after a successful rights issue.
Julphar starts on a fresh chapter from July 28, with the launch of trading after a successful rights issue.
Gulf News Archive

Dubai: The Ras Al Khaimah based pharma company Julphar has completed its capital restructure programme, raising its share capital by Dh500 million to Dh1.15 billion. This was done through a rights issue, which was heavily subscribed.

The new shares have started trading from today.

Earlier, Julphar reduced its issued share capital by Dh503.27 million to Dh655.27 million. This was done by cancelling 503.27 million shares.

The capital reduction was done through share cancellation equivalent to the accumulated losses of Dh503.27 million as of end 2019.

Sign up for the Daily Briefing

Get the latest news and updates straight to your inbox

Up Next